Posted by Michael Wonder on 19 May 2022
NeuroMetrix reports that Quell wearable neuromodulation device has received FDA de novo authorisation as first non-pharmacological treatment for fibromyalgia
19 May 2022 - NeuroMetrix today announced U.S. FDA de novo authorisation to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.
The Company received FDA breakthrough designation for the use of Quell to treat fibromyalgia in July 2021.
